Search Results

You are looking at 1 - 10 of 17 items for :

  • "lenalidomide" x
  • All content x
Clear All

targeted therapy of del (5q) MDS. Cancer Cell 2014; 26: 509–520. 10 Pellagatti A, Jadersten M, Forsblom AM, et al. Lenalidomide inhibits the malignant

Open access
Orvosi Hetilap
Authors: Gergely Varga, Gábor Mikala, László Váróczy, and Árpád Illés

, K. A., Jasielec, J.: Phase II MMRC trial of extended treatment with carfilzomib, lenalidomide, and dexamethasone plus autologous stem cell transplantation in newly diagnosed multiple myeloma

Open access

Irodalom 1 Liu C, Ghobrial I, Bustoros M, et al. Phase II trial of combination of elotuzumab, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma

Restricted access
Hematológia–Transzfuziológia
Authors: András Kozma, Melinda Paksi, Emma Ádám, András Bors, Hajnalka Andrikovics, and Gábor Mikala

–147. 7 Mossner M, Jann JC, Nowak D, et al. Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide

Restricted access
Orvosi Hetilap
Authors: Klára Gadó and Gyula Domján

2010 90 905 911 Sanchorawala, V., Wright, D. G., Rosenzweig, M., et al.: Lenalidomide and dexamethasone in

Open access
Orvosi Hetilap
Authors: Nikolett Wohner, Gergely Varga, Péter Szloboda, Péter Farkas, András Masszi, Laura Horváth, Gergely Szombath, Judit Várkonyi, Szabolcs Benedek, and Tamás Masszi

. 2009; 10: 1–15. 9 Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011; 118

Open access

Barca E, et al.: Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 2020; 21: 978

Open access

response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma. Ann. Hematol. 2014; 93: 1371–1380. 3 Dasgupta RK

Restricted access

the future. Best Pract Res Clin Haematol. 2020; 33: 101140. 3 Ishida T, Kimura H, Ozaki S, et al. Continuous lenalidomide treatment after bortezomib

Open access
Orvosi Hetilap
Authors: Dóra Földeák, Attila Nemes, Anita Kalapos, Péter Domsik, Árpád Kormányos, László Krenács, Enikő Bagdi, and Zita Borbényi

–4394. 45 Moreau P, Jaccard A, Benboubker L, et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study

Restricted access